Leadman Biochemistry moves ahead with major asset restructuring

Beijing Leadman Biochemistry Co., Ltd. is in the process of acquiring up to 70% of the shares in Beijing Xiansheng Xiangrui Biological Products Co., Ltd. This transaction, expected to constitute a major asset restructuring, will grant Beijing Leadman Biochemistry control over the target company, making it a holding subsidiary. The company previously signed an investment framework agreement on July 30, 2025, with the target company and its shareholders.

On November 13, 2025, the company signed a share purchase agreement and performance commitment and compensation agreement with the target company's shareholders. The same day, the company's Sixth Board of Directors and Sixth Board of Supervisors approved the proposal on the listed company's major asset restructuring and related proposals. Detailed reports were disclosed on November 13, 2025, on www.cninfo.com.cn.

The transaction remains subject to approval by the company's shareholders' meeting, relevant state-owned asset supervision and administration, confirmation of compliance from the National Equities Exchange and Quotations, and other regulatory approvals. The company emphasizes that there are uncertainties regarding the timing and successful acquisition of these approvals, urging investors to be aware of the investment risks.